as a ligand-inducible connection to control the function and localization of engineered
proteins in mammalian cells. To demonstrate the versatility of this approach, we designed
drug-sensitive transcription factors and transmembrane signaling proteins, the activities of
which can be tightly and reversibly controlled through the use of clinically tested antiviral
protease inhibitors.